Clinical Data QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS BioSpaceBiogen's Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis.NeuroscienceRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) BioSpace Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beatNext: Viridian data lift prospects for thyroid eye disease drug Related Stories Clinical Data Parkinson’s drug from Biogen, Denali comes up short pharminent May 22, 2026 Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026 Clinical Data Lilly’s triple agonist shows bariatric surgery-like weight loss results pharminent May 21, 2026
